R Elsby

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi request reprint Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions
    R Elsby
    Development Drug Metabolism and Pharmacokinetics and Bioanalysis Charnwood, Loughborough, UK
    Xenobiotica 38:1140-64. 2008
  2. doi request reprint The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK
    Drug Metab Dispos 39:275-82. 2011
  3. doi request reprint Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1
    R Elsby
    Global DMPK In Vitro In Silico ADME, AstraZeneca R and D Alderley Park, Cheshire, UK
    Clin Pharmacol Ther 92:584-98. 2012
  4. doi request reprint In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca Research and Development Charnwood, Loughborough, Leicestershire, United Kingdom
    Eur J Pharm Sci 43:41-9. 2011
  5. doi request reprint Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Loughborough, Leicestershire, UK
    Xenobiotica 41:764-83. 2011
  6. doi request reprint Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions
    P Sharma
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Loughborough LE11 5RH, UK
    Xenobiotica 40:24-37. 2010

Collaborators

  • P Sharma
  • C Lambert
  • V E Holmes
  • D Surry

Detail Information

Publications6

  1. ncbi request reprint Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions
    R Elsby
    Development Drug Metabolism and Pharmacokinetics and Bioanalysis Charnwood, Loughborough, UK
    Xenobiotica 38:1140-64. 2008
    ..They have been successfully applied to development projects resulting in the identification of two candidate drugs as substrates and inhibitors of P-gp, whereas a third was neither a substrate nor an inhibitor of this transporter...
  2. doi request reprint The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK
    Drug Metab Dispos 39:275-82. 2011
    ..The observed dose-dependent clinically significant interaction was accurately predicted using calculated [I(2)] and in vitro P-gp inhibition data, confirming AZD5672 to be a P-gp inhibitor in vivo...
  3. doi request reprint Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1
    R Elsby
    Global DMPK In Vitro In Silico ADME, AstraZeneca R and D Alderley Park, Cheshire, UK
    Clin Pharmacol Ther 92:584-98. 2012
    ..Finally, on a statin-by-statin basis, we propose in vitro inhibition studies that should be routinely conducted during drug development so as to better assess DDI risk...
  4. doi request reprint In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca Research and Development Charnwood, Loughborough, Leicestershire, United Kingdom
    Eur J Pharm Sci 43:41-9. 2011
    ....
  5. doi request reprint Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions
    Robert Elsby
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Loughborough, Leicestershire, UK
    Xenobiotica 41:764-83. 2011
    ..The approach builds on earlier validations to support drug registration and extends from those cell-based systems to encompass assay formats using membrane vesicles...
  6. doi request reprint Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions
    P Sharma
    Clinical Pharmacology and DMPK, AstraZeneca R and D Charnwood, Loughborough LE11 5RH, UK
    Xenobiotica 40:24-37. 2010
    ..These validated OATP1B1 assays were robust, reproducible, and suitable for routine in vitro evaluation of candidate drugs...